Life Care Center Of Acton | |
One Great Road, Acton, Massachusetts 01720 | |
(978) 263-9101 | |
Name | Life Care Center Of Acton |
---|---|
Location | One Great Road, Acton, Massachusetts |
Certified By | Medicare and Medicaid |
No. of Certified Beds | 155 |
Occupancy Rate | 54.84% |
Medicare ID (CCN) | 225191 |
Legal Business Name | Life Care Centers Of America, Inc. |
Ownership Type | For Profit - Corporation |
NPI Number | 1356304265 |
Organization Name | LIFE CARE CENTERS OF AMERICA, INC. |
Doing Business As | LIFE CARE CENTER OF ACTON |
Address | 1 Great Rd, Acton, MA 01720 |
Phone Number | 978-263-9101 |
News Archive
Urodynamix Technologies Ltd. (TSX VENTURE:URO) today announced that a cross of 1,480,000 common shares has been effected through Canaccord Capital Inc. at a sales price of $0.05 per common share.
Significant new data presented today at the International Liver Congress- 2014 indicate that liver cancer (Hepatocellular Carcinoma (HCC)) may be treated by adoptive T-cell therapy.
Elsevier Middle East announces that the Journal of Infection and Public Health (JIPH) has been selected for inclusion in MEDLINE, the premier bibliographic database of the U.S. National Library of Medicine (NLM). Citations for articles indexed, the indexing terms and the abstract printed in the journal are now searchable using PubMed (http://www.pubmed.gov). Indexing using the US National Library of Medicine's (NLM) advanced MeSH terminology will be retroactive from Volume 1, Issue 1 (2008) of the journal.
Sequella, Inc., a clinical-stage biopharmaceutical company focused on commercializing novel antibiotics to treat life-threatening infectious diseases, today announced that it received a $594,661 two-year Small Business Innovative Research (SBIR) grant from the National Institutes of Health (NIH), National Institute of Allergy and Infectious Diseases (NIAID) for the development of SQ641, Sequella's lead compound in its capuramycin series, a new class of antibiotic.
› Verified 3 days ago
Ratings from Surveys (Inspections): | |
Ratings from Quality Measures: | |
Ratings from Staffing Data: | |
Overall Rating: |
---|
News Archive
Urodynamix Technologies Ltd. (TSX VENTURE:URO) today announced that a cross of 1,480,000 common shares has been effected through Canaccord Capital Inc. at a sales price of $0.05 per common share.
Significant new data presented today at the International Liver Congress- 2014 indicate that liver cancer (Hepatocellular Carcinoma (HCC)) may be treated by adoptive T-cell therapy.
Elsevier Middle East announces that the Journal of Infection and Public Health (JIPH) has been selected for inclusion in MEDLINE, the premier bibliographic database of the U.S. National Library of Medicine (NLM). Citations for articles indexed, the indexing terms and the abstract printed in the journal are now searchable using PubMed (http://www.pubmed.gov). Indexing using the US National Library of Medicine's (NLM) advanced MeSH terminology will be retroactive from Volume 1, Issue 1 (2008) of the journal.
Sequella, Inc., a clinical-stage biopharmaceutical company focused on commercializing novel antibiotics to treat life-threatening infectious diseases, today announced that it received a $594,661 two-year Small Business Innovative Research (SBIR) grant from the National Institutes of Health (NIH), National Institute of Allergy and Infectious Diseases (NIAID) for the development of SQ641, Sequella's lead compound in its capuramycin series, a new class of antibiotic.
› Verified 3 days ago
Number of Facility Reported Incidents | 0 |
Number of Substantiated Complaints | 0 |
Number of Fines | 1 |
Total Amount of Fines in Dollars | $3250 |
Number of Payment Denials | 0 |
Total Number of Penalties | 1 |
Experience Measure | Provider | National Avg. |
---|---|---|
Percentage of long-stay residents whose need for help with daily activities has increased | 14.52 | 14.46 |
Percentage of long-stay residents who lose too much weight | 9.3 | 5.51 |
Percentage of low risk long-stay residents who lose control of their bowels or bladder | 75.18 | 48.41 |
Percentage of long-stay residents with a catheter inserted and left in their bladder | 0.25 | 1.79 |
Percentage of long-stay residents with a urinary tract infection | 2.4 | 2.65 |
Percentage of long-stay residents who have depressive symptoms | 4.36 | 5.05 |
Percentage of long-stay residents who were physically restrained | 0 | 0.23 |
Percentage of long-stay residents experiencing one or more falls with major injury | 4.17 | 3.36 |
Percentage of long-stay residents assessed and appropriately given the pneumococcal vaccine | 100 | 93.87 |
Percentage of long-stay residents who received an antipsychotic medication | 14.98 | 14.2 |
Percentage of short-stay residents assessed and appropriately given the pneumococcal vaccine | 95.98 | 83.88 |
Percentage of short-stay residents who newly received an antipsychotic medication | 1.12 | 1.79 |
Percentage of long-stay residents whose ability to move independently worsened | 30.58 | 17.09 |
Percentage of long-stay residents who received an antianxiety or hypnotic medication | 17.99 | 19.7 |
Percentage of high risk long-stay residents with pressure ulcers | 6.93 | 7.32 |
Percentage of long-stay residents assessed and appropriately given the seasonal influenza vaccine | 100 | 95.98 |
Percentage of short-stay residents who made improvements in function | 58.95 | 67.99 |
Percentage of short-stay residents who were assessed and appropriately given the seasonal influenza vaccine | 94.61 | 82.93 |
News Archive
Urodynamix Technologies Ltd. (TSX VENTURE:URO) today announced that a cross of 1,480,000 common shares has been effected through Canaccord Capital Inc. at a sales price of $0.05 per common share.
Significant new data presented today at the International Liver Congress- 2014 indicate that liver cancer (Hepatocellular Carcinoma (HCC)) may be treated by adoptive T-cell therapy.
Elsevier Middle East announces that the Journal of Infection and Public Health (JIPH) has been selected for inclusion in MEDLINE, the premier bibliographic database of the U.S. National Library of Medicine (NLM). Citations for articles indexed, the indexing terms and the abstract printed in the journal are now searchable using PubMed (http://www.pubmed.gov). Indexing using the US National Library of Medicine's (NLM) advanced MeSH terminology will be retroactive from Volume 1, Issue 1 (2008) of the journal.
Sequella, Inc., a clinical-stage biopharmaceutical company focused on commercializing novel antibiotics to treat life-threatening infectious diseases, today announced that it received a $594,661 two-year Small Business Innovative Research (SBIR) grant from the National Institutes of Health (NIH), National Institute of Allergy and Infectious Diseases (NIAID) for the development of SQ641, Sequella's lead compound in its capuramycin series, a new class of antibiotic.
› Verified 3 days ago